Clinical Trial: Oral CBD Administration Provides Relief From Dental Pain
San Antonio, TX: A single oral dose of plant-derived CBD provides short-term relief from acute dental pain, according to randomized, placebo-controlled trial data published in the Journal of Dental Research.
Investigators affiliated with the University of Texas at San Antonio assessed the efficacy of CBD (in the form of Epidiolex) versus placebo in a cohort of 61 patients with severe dental pain. Subjects received a dose of either 10 mg, 20 mg, or placebo CBD. A visual analog scale assessed patients’ pain levels before and after treatment.
Researchers reported, “Both CBD groups resulted in significant VAS pain reduction compared to their baseline and the placebo group, with a maximum median VAS pain reduction of 73 percent from baseline pain at the 180-min time point.” Side-effects associated with CBD were “minimal.”
Authors concluded: “This randomized trial provides the first clinical evidence that oral CBD can be an effective and safe analgesic for dental pain. … This novel study can catalyze the use of CBD as an alternative analgesic to opioids for acute inflammatory pain conditions, which could ultimately help to address the opioid epidemic.”
Epidiolex is a proprietary CBD product derived from cannabis plants manufactured by the British biotechnology firm GW Pharmaceuticals. The FDA approved it in 2018 as a prescription-only treatment for rare seizure disorders. The DEA descheduled it in April 2020.
Full text of the study, “Cannabidiol as an alternative analgesic for acute dental pain,” appears in theJournal of Dental Research.
Meta-Analysis: Cannabis Use Associated With Weight Loss, Lower BMI
Belo Horizonte, Brazil: Subjects who consume cannabis or cannabis-related products in clinical trials typically experience weight loss, according to a meta-analysis published in the International Journal of Obesity.
Brazilian researchers reviewed results from randomized controlled trials involving subjects’ use of cannabis or cannabis-related products.
They reported: “In general, cannabis use reduced weight ... and WC [waist circumference]. When examining subgroups, longer follow-up periods were associated with a more pronounced BMI [body mass index] reduction.”
The study’s authors concluded, “These findings suggest that cannabis and sub-products could be considered adjuncts in obesity treatment by helping to reduce relevant anthropometric measurements.”
A 2022 ecological analysis published in the journal Health Economics reported that the adoption of state-licensed marijuana sales is associated with a decrease in state-level obesity rates.
Case-control studies have consistently reported that those with a history of marijuana use are less likely than abstainers to be obese or to suffer from type 2 diabetes. Studies have also previously linked cannabis use to greater rates of physical activity.
Full text of the study, “Effects of cannabis and sub-products on anthropometric measures: A systematic review and meta-analysis,” appears in the International Journal of Obesity.
Study: Subjects Report That CBD Products Provide Stress Relief
Detroit, MI: CBD oil products provide stress relief, according to data published in the journal Medical Cannabis and Cannabinoids.
Investigators affiliated with Wayne State University’s School of Medicine assessed the short-term use of CBD products in a cohort of 374 participants. Study subjects were instructed to use a 1,000mg hemp-derived CBD isolate product ad libitum for the first half of the trial period. They were then instructed to switch to a 1,000mg broad-spectrum hemp-derived product for the remainder of the study.
Third-party testing confirmed that the isolate product contained CBD and no other cannabinoids. By contrast, the broad-spectrum product contained CBD, CBG, and other cannabinoids, as well as various terpenes.
Researchers reported, “Overall, both products were rated to be highly effective and able to assist with stress management.” However, they added, “Ratings were higher for the broad spectrum as compared to the isolate product, which is consistent with prior data suggesting that cannabinoids can work synergistically to maximize benefits.”
There were no differences in adverse effect ratings for the two products.
The study’s authors concluded: “This quasi-experimental study of nearly 400 adult volunteers compared self-reported effectiveness of two THC-free CBD products -- an isolate and a broad spectrum -- for stress reduction. Overall, participants reported both CBD products to be effective and able to assist with stress management, and that ratings were higher for the broad spectrum as compared to the isolate product. … Together, these data fit with prior studies, suggesting anti-stress effects of CBD. Nonetheless, more controlled studies are needed to explore these effects in both nonclinical and clinical populations.”
Full text of the study, “Effects of two cannabidiol oil products on self-reported stress relief: A quasi-experimental study,” appears in Medical Cannabis and Cannabinoids.
Study: Subjects Report That CBD Products Provide Stress Relief
Detroit, MI: CBD oil products provide stress relief, according to data published in the journal Medical Cannabis and Cannabinoids.
Investigators affiliated with Wayne State University’s School of Medicine assessed the short-term use of CBD products in a cohort of 374 participants. Study subjects were instructed to use a 1,000mg hemp-derived CBD isolate product ad libitum for the first half of the trial period. They were then instructed to switch to a 1,000mg broad-spectrum hemp-derived product for the remainder of the study.
Third-party testing confirmed that the isolate product contained CBD and no other cannabinoids. By contrast, the broad-spectrum product contained CBD, CBG, and other cannabinoids, as well as various terpenes.
Researchers reported, “Overall, both products were rated to be highly effective and able to assist with stress management.” However, they added, “Ratings were higher for the broad spectrum as compared to the isolate product, which is consistent with prior data suggesting that cannabinoids can work synergistically to maximize benefits.”
There were no differences in adverse effect ratings for the two products.
The study’s authors concluded: “This quasi-experimental study of nearly 400 adult volunteers compared self-reported effectiveness of two THC-free CBD products -- an isolate and a broad spectrum -- for stress reduction. Overall, participants reported both CBD products to be effective and able to assist with stress management, and that ratings were higher for the broad spectrum as compared to the isolate product. ... Together, these data fit with prior studies, suggesting anti-stress effects of CBD. Nonetheless, more controlled studies are needed to explore these effects in both nonclinical and clinical populations.”
Full text of the study, “Effects of two cannabidiol oil products on self-reported stress relief: A quasi-experimental study,” appears in Medical Cannabis and Cannabinoids.
